Bone Morphogenetic Protein-8b (bmp8b) as Marker and Therapeutic Target for Liver Fibrosis or Liver Cancer

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes the use of inhibitors targeting bone morphogenetic protein-8B (BMP8B) as a method to prevent or treat liver fibrosis and liver cancer. It also introduces diagnostic methods and kits for detecting BMP8B as a biomarker to diagnose and monitor the progression of these liver conditions. The proposed BMP8B inhibitors include oligonucleotides (such as siRNA, miRNA, and antisense sequences), antibodies, small molecules, or a combination. By inhibiting BMP8B or measuring its concentration in blood or tissue samples, this invention offers new ways to identify, track, and manage liver fibrosis and liver cancer.

Use CasesContent extracted from patent full text and abstract with AI.

• Therapeutic treatment of patients with liver fibrosis using BMP8B inhibitors to reduce or halt disease progression.
• Therapeutic treatment of patients with liver cancer using BMP8B inhibitors to inhibit tumor growth.
• Non-invasive diagnosis of liver fibrosis and liver cancer by detecting elevated BMP8B levels in blood or tissue samples.
• Monitoring disease progression or response to therapy in liver fibrosis and liver cancer patients through regular BMP8B assessments.
• Stratifying patients most likely to benefit from BMP8B inhibitor treatment based on biomarker levels.
• Companion diagnostic testing to guide use of BMP8B inhibitors in personalized medicine programs.
• Development and commercialization of diagnostic kits for clinical laboratories to test for BMP8B as a liver disease biomarker.

BenefitsContent extracted from patent full text and abstract with AI.

• Provides a novel, specific therapeutic target (BMP8B) for both liver fibrosis and liver cancer, diseases with limited current treatments.
• Enables earlier and more accurate diagnosis of liver fibrosis and liver cancer using a measurable biomarker, potentially before severe damage occurs.
• Allows non-invasive monitoring and staging of liver fibrosis and liver cancer, reducing need for liver biopsies.
• Supports personalized medicine by identifying candidates likely to benefit from BMP8B-targeted therapies.
• Potential to improve patient survival and outcomes via earlier intervention and targeted treatment.
• Combines diagnostic and therapeutic innovations, facilitating faster and better-informed clinical decisions.
• Compatibility with various sample types (blood, tissue), and detection technologies (ELISA, PCR, etc.), supporting broad clinical integration.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention refers to BMP8B-inhibitor for use in a method of preventing and/or treating liver fibrosis and/or liver cancer, wherein the inhibitor is an oligonucleotide, an antibody or fragment thereof, a small molecule or a combination thereof. Further, the invention is directed to a method for diagnosing liver fibrosis and/or liver cancer and a kit for diagnosing fibrosis and/or cancer. The method and the kit can be used to identify a subject in need for a BMP8B-inhibitor to prevent and/or treat liver fibrosis and/or liver cancer.